For more than sixty years, The Leukemia & Lymphoma Society (LLS) has supported groundbreaking and lifesaving research. One of the most notable researchers LLS has supported is Brian Druker, M.D. He was a leader during the 1990s in the development of Gleevec, a revolutionary "targeted therapy" approved by the FDA in 2001 for patients with chronic myeloid leukemia. Recent studies show that more than 90% of nearly diagnosed early stage chronic myeloid leukemia patients can expect to survive long-term. Dr. Druker is a large reason why that number is so high.
Watch this video to find out what piqued Dr. Druker's interest in blood cancers early in his career.